Chiasma Inc

Chiasma — Merger or Acquisition (May 2021)

32 slides from Chiasma's merger presentation, May 5, 2021

  1. Slide 1: All Company Employee Meeting May 5, 2021

    All Company Employee Meeting May 5, 2021 Filed by: Chiasma, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Chiasma, Inc. Commission File No: 001-37500

  2. Slide 2: Agenda

    Agenda Welcome, Setting the Scene for TodayRaj Kannan Who am I? Who is Amryt?Dr Joe Wiley Next Steps & CloseJoe

  3. Slide 3: Forward-looking statements notice

    This communication relates to a proposed business combination transaction between Amryt Pharma plc (“Amryt”) and Chiasma, Inc. (“Chiasma”). This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchang

  4. Slide 4: No Offer or Solicitation; Additional Information

    No Offer or Solicitation This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer,

  5. Slide 5: Q&A: What was announced today?

    Q&A: What was announced today? What was announced today? Prior to the opening of the markets today, Chiasma announced that it has entered into a definitive merger agreement pursuant to which Chiasma will be acquired by Amryt Pharma Plc in an all-stock transaction. If this transaction closes, Chiasma

  6. Slide 6: Q&A: Deal rationale and timing

    Q&A: Deal rationale and timing What is the rationale for Chiasma to merge with AMRYT? What is the timing of the proposed transaction? The transaction agreement was signed on May 4, 2021, and the closing is expected to occur during the third quarter of 2021. The transaction is subject to the approval

  7. Slide 7: Q&A: Deal overview and activities

    Q&A: Deal overview and activities What is the difference between deal signing and deal closing? Deal signing means that both parties, Chiasma and Amryt, have signed a definitive merger agreement that reflects the terms of the proposed transaction, the arrangements between the parties for the period

  8. Slide 8: Q&A: Organization and site

    Q&A: Organization and site What will happen to Chiasma? Upon closing of the transaction, Chiasma will become a subsidiary of Amryt and its business and operations will be integrated into those of Amryt. Amryt’s strong global commercial and medical infrastructure will be further enhanced by Chiasma’s

  9. Slide 9: Q&A: Programs and Platforms

    Q&A: Programs and Platforms What will happen to Chiasma’s commercial organization and launch? This is a critical time for Chiasma and we must maintain momentum for patients and for each other. We are committed to operating in the ordinary course during this time. The transaction is intended to lever

  10. Slide 10: Q&A: Employee Impact (1 of 2)

    Q&A: Employee Impact (1 of 2) What is Amryt’s culture like? Will Chiasma’s culture change? Like Chiasma, AMRYT shares common core beliefs – unwavering commitment to their patients and their employees, passionate about delivering innovative treatments to patients in need, ingenuity in execution, and

  11. Slide 11: Q&A: Employee Impact (2 of 2)

    Q&A: Employee Impact (2 of 2) Will there be a restructuring or reduction in force? We continue to operate as separate companies until the deal is closed, which is expected in the third quarter of 2021. As the integration plans materialize, we anticipate that both retention and severance plans will b

  12. Slide 12: Q&A: Public Communications

    Q&A: Public Communications Can employees talk about the proposed business combination publicly? Employees are free to talk about the transaction using only the publicly available information provided by Chiasma. All inquiries about the acquisition from the media or other external parties should be d

  13. Slide 13: Q&A: Equity and Trading restrictions

    Q&A: Equity and Trading restrictions How will the acquisition affect employee equity and stock options? Restricted Stock Units (“RSUs”): At closing, all outstanding Chiasma RSUs will convert into RSUs for Amryt ADSs based on the fixed exchange ratio. Stock Options: Outstanding vested and unvested Ch

  14. Slide 14: Welcome to AMRYT

    Welcome to AMRYT Joe Wiley, CEO

  15. Slide 15: Disclaimer

    Disclaimer This presentation has been prepared by the Company. “Presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the meeting. By receiving this presentation and/or attending the meeting where th

  16. Slide 16: Who am I? Amryt

    WHO AM I? CONFIDENTIAL AMRYT

  17. Slide 17: Chiasma: My P's and Q

    « CHIASMA MY P’s AND Q

  18. Slide 18: Watching my p's: Performance, Purpose, Patients, People

    Watching my p’s PERFORMANCE PURPOSE PATIENTS PEOPLE Confidential

  19. Slide 19: Our Vision, Our Future – Amryt 2025

    OUR VISION, OUR FUTURE – Amryt 2025 To become a leading global rare disease company by acquiring, developing and commercializing medicines that transform the lives of patients & their families around the world Confidential

  20. Slide 20: Our Purpose – What We Do Every Day

    OUR PURPOSE – WHAT WE DO EVERY DAY “We transform the lives of people affected by rare, debilitating conditions by providing innovative medicines that bring hope to those in greatest need” Confidential

  21. Slide 21: With Metreleptin we help patients with lipodystrophy

    With Metreleptin we help patients with LIPODYSTROPHY fatty liver Insatiable appetite chronic fatigue Diabetes Pancreatitis Organ damage Reduced life expectancy Lipodystrophy is a chronic condition associated with low leptin levels as a result of the loss of adipose tissue. Leptin is an important hor

  22. Slide 22: With Lomitapide we help patients with HoFH

    With LOMITAPIDE we help patients with HoFH Lomitapide is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal treatments for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Columbia, Argentina and Japan (under th

  23. Slide 23: Oleogel-s10 (Filsuvez) – potential first therapy for epidermolysis bullosa

    Oleogel-s10 (Filsuvez®)* – Potential first in market therapy for epidermolysis bullosa, where the unmet is elevated Regulatory submissions filed with FDA and EMA. If approved, U.S. launch anticipated Q4 2021 EU anticipated Q2 2022 Received Fast Track Designation Granted Rare Pediatric Disease Design

  24. Slide 24: Mycapssa – serving a high unmet need in endocrinology

    Mycapssa – serving a high unmet need in endocrinology Octreotide and lanreotide injections are broadly used as first-line pharmacological treatments Injections Present Significant Challenges to Patients The global market for SSAs in the treatment of acromegaly is estimated at ~$800 million with U.S.

  25. Slide 25: Global infrastructure in place to drive global growth

    GLOBAL INFRASTRUCTURE in place to drive global growth 7 Current markets Pending markets Out-licensed BA Pharma Trading Ltd Confidential

  26. Slide 26: Stronger together

    Stronger together Amryt Chiasma Amryt Chiasma Combined Commercial Products 2 marketed products with multiple lifecycle extension opportunities 1 marketed product in first full year of launch 3 marketed products with strong IP protection Infrastructure Global medical + commercial U.S. medical + comme

  27. Slide 27: Growing commercial portfolio and enhanced development pipeline

    GROWING COMMERCIAL PORTFOLIO & ENHANCED Development Pipeline EARLY AND LATE-STAGE PIPELINE WITH MULTIPLE VALUE INFECTION POINTS Definitions: Dystrophic EB (“DEB”); Junctional EB (‘‘JEB’’); Recessive Dystrophic EB (‘‘RDEB’’) * Upcoming clinical milestones are subject to the impact of COVID-19 on our

  28. Slide 28: Our Purpose – What We Do Every Day

    OUR PURPOSE – WHAT WE DO EVERY DAY “We transform the lives of people affected by rare, debilitating conditions by providing innovative medicines that bring hope to those in greatest need” MISSION: Replace painful injectable therapies with oral formulations so people can live better lives Confidentia

  29. Slide 29: Amryt and Chiasma share a common culture defined by shared values

    Amryt and chiasma share a common culture defined by shared values Our shared values will be the foundation for us to realize our vision as one new company TOGETHER PURPOSE PATIENTS PERFORMANCE PEOPLE Confidential Chiasma Values Persistence Passion for Results Sense of Urgency Commitment To People In

  30. Slide 30: And the Q? What does this mean for me?

    And the Q? What does this mean for me? Confidential

  31. Slide 31: Next steps – We want to hear your voice

    Next steps – We want to hear your voice On Tuesday May 11 we will meet again to provide an opportunity have conversations in smaller groups You will get an opportunity to meet and get to know key leaders from Amryt Confidential

  32. Slide 32: We are stronger & better, together as one

    We are stronger & better, together as one Confidential

Chiasma — Merger or Acquisition (May 2021) on 6ix